A quantitative assessment of oral contraceptive use and risk of ovarian cancer

Hankinson, SE; Colditz, GA; Hunter, D.J.; Spencer, TL; Rosner, B; Stampfer, MJ

doi:10.1016/0020-7292(93)90732-c

Cited by 99 publications

(78 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a review a 50% reduced risk was calculated after 5 years on the pill (Stanford, 1991). A similar result was documented in a meta-analysis (Hankinson et al, 1992), with each year of OC use contributing 10-12% to the risk reduction.…”

Section: Combined Oral Contraceptivessupporting

confidence: 55%

“…In the above cited meta-analysis a summary relative risk of 0·55 was found for both nulliparous and parous women (Hankinson et al, 1992). An effect modification of parity on the relation between OC use and epithelial ovarian cancer may exist.…”

Section: Combined Oral Contraceptivesmentioning

confidence: 96%

“…Protection from ever use of OC has appeared in a large majority of studies (Newhouse et al, 1977;Annegers et al, 1979;Casagrande et al, 1979;McGowan et al, 1979;Willett et al, 1981;Weiss et al, 1981;Hildreth et al, 1981;Franceschi et al, 1982LaVecchia et al, 1984;Tzonou et al, 1984;CASH, 1987;Vessey et al, 1987;Beral et al, 1988;Wu et al, 1988;WHO, 1989;Booth et al, 1989;Gwinn et al, 1990;Parazzini et al, 1991;Rosenblatt et al, 1992;Whittemore et al, 1992;Tavani et al, 1993;Risch et al, 1994;Rosenberg et al, 1994;Hankinson et al, 1995;Purdie et al, 1995;Vessey & Painter, 1995). A meta-analysis including 20 studies from the 1970s and the 1990s calculated a summary relative risk of 0·64 (95% confidence interval 0·57-0·73) for ever use of OC (Hankinson et al, 1992). One study found no association between OC use and epithelial ovarian cancer risk (Hartge et al, 1989).…”

Section: Combined Oral Contraceptivesmentioning

confidence: 99%

See 2 more Smart Citations

Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence

Riman

Persson

Nilsson

1998

Clinical Endocrinology

172

120

View full text Add to dashboard Cite

Section: Combined Oral Contraceptivessupporting

confidence: 55%

Section: Combined Oral Contraceptivesmentioning

confidence: 96%

Section: Combined Oral Contraceptivesmentioning

confidence: 99%

See 1 more Smart Citation

Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence

Riman

Persson

Nilsson

1998

Clinical Endocrinology

172

120

View full text Add to dashboard Cite

“…The few known risk factors are either reproductive related [decreased risk from oral contraceptive use (2), parity (3), and long-term breastfeeding (3)] or represent inherited mutations in a few high-risk, high-penetrance genes (e.g., BRCA1; ref. 4).…”

Section: Introductionmentioning

confidence: 99%

Genetic Variation in the One-Carbon Transfer Pathway and Ovarian Cancer Risk

Kelemen¹,

Sellers

Schildkraut

et al. 2008

Cancer Research

View full text Add to dashboard Cite

Dysfunction in enzymes involved in one-carbon (1-C) metabolism can lead to increased chromosomal strand breaking and abnormal methylation patterns, which are both associated with cancer risk. Availability of 1-C units may modify risk. We investigated the association of single-nucleotide polymorphisms (SNP) in 21 genes in the 1-C transfer pathway among 829 Caucasian cases with primary epithelial ovarian cancer and 941 frequency-matched unaffected controls enrolled at Mayo Clinic (Rochester, MN) and Duke University (Durham, NC) and examined risk modification by multivitamin supplement use. Multivariable-adjusted SNP-specific logistic regression and haplotype analyses were done for 180 SNPs and false positive report probabilities (FPRP) were calculated. Each copy of the minor allele in SHMT1 intron 5 A>G (rs9909104) was associated with epithelial ovarian cancer [odds ratio (OR), 1.2; 95% confidence interval (95% CI), 1.0-1.4; P trend = 0.02; FPRP = 0.16] and a 5-SNP SHMT1 haplotype was associated with decreased risk (P = 0.01; FPRP = 0.09). Three SNPs in DNMT3A were associated with risk among multivitamin supplement users: 3 ¶ untranslated region (UTR) C>G (rs13420827: OR, 0.8; 95% CI, 0.6-1.0; P interaction = 0.006; FPRP = 0.54), intron 6 G>A (rs11887120: OR, 0.8; 95% CI, 0.7-1.0; P interaction = 0.007; FPRP = 0.57), and intron 22 A>T (rs11695471: OR, 1.2; 95% CI, 1.0-1.5; P interaction = 0.01; FPRP = 0.66). These data extend previous findings from other cancers of a role for SHMT1 in ovarian cancer, and provide evidence that SNPs in methylation and DNA synthesis reactions are associated with risk of ovarian cancer. Interventions with modifiable factors such as multivitamin intake may reduce risk. [Cancer Res 2008;68(7):2498-506]

show abstract

“…For example, for ovarian cancer we may consider defining a low-risk group that may include women who have used oral contraceptives for five or more years (which yields a 50 percent reduction in risk) (Hankinson et al 1992), who do not have a family history of breast or ovarian cancer, and who have had a tubal ligation (which further reduces risk by approximately 50 percent) (Hankinson et al 1993). This may be a rare example among cancers, although colon cancer may also offer the potential to define risk groups according to lifestyle factors and to recommend screening strategies separately for these groups (e.g., high-riskdefined by intake of red meat, moderate alcohol intake, and low folate intake; low-risk-defined by low red meat, low alcohol, and high folate intake) (Giovannucci et al 1993).…”

Section: Discussionmentioning

confidence: 99%

Cancer Incidence and Mortality: The Priority of Screening Frequency and Population Coverage

1997

View full text Add to dashboard Cite

N a t i o n a l p r o g r a m s o f t e n a r e d e s i g n e d t oreduce the impact of a major health problem. Yet the available research base that informs these policy decisions does not always provide the answers to some critical questions. The national health promotion and disease prevention objectives for the United States, which were devised to prevent and control cancer by the year 2000, include recommendations to increase the use of screening for breast, cervical, and colorectal cancers (U.S. Department of Health and Human Services 1990):• increase the coverage of clinical breast exams and mammography every two years to at least 60 percent of women aged 50 and older • increase the coverage of Pap tests every one to three years to at least 85 percent of women aged 18 and older • increase fecal occult blood testing every one to two years to at least 50 percent of people aged 50 and olderThe availability of further data or consideration of additional issues might improve these recommendations. The U.S.

show abstract

A quantitative assessment of oral contraceptive use and risk of ovarian cancer

Cited by 99 publications

References 0 publications

Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence

Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence

Genetic Variation in the One-Carbon Transfer Pathway and Ovarian Cancer Risk

Cancer Incidence and Mortality: The Priority of Screening Frequency and Population Coverage

Contact Info

Product

Resources

About